Skip to main content

AlphaLISA Human KEAP1 Binding Kit, 500 Assay Points

The AlphaLISA® Human KEAP1 Binding Kit is designed to screen and characterize compounds that specifically bind the E3 ligase, KEAP1, using Alpha Technology.

Part Number: AL3194C
Unit Size:
Part Number: AL3194F
Unit Size:
  • Kelch-like ECH-associated protein 1 (KEAP1) is an adaptor subunit of Cullin 3-based E3 ubiquitin ligase involved in oxidative stress response. By promoting UPS mediated degradation, KEAP1 controls the expression level of key proteins such as NRF2, a transcription factor controlling the expression of antioxidant proteins. Sustained activation of NRF2 has been associated to cancers resistance, and its inhibition has been shown to dampen drugs resistance. Targeted protein degradation (TPD) uses small molecules to recruit E3 ubiquitin ligases into the proximity of the targeted protein of interest, promoting its ubiquitination-dependent degradation. Exploiting KEAP1 inhibitors for the development of bifunctional Proteolysis-targeting chimeras (PROTACs) is expected to expand the toolbox of E3 ligases to removing undesired proteins (e.g., NRF2) involved in various diseases such as cancers, neurodegenerative diseases, and metabolic disorders.

    Formats
    • Our 500 assay point kit allows you to run 500 wells in a 384-well format, using a 20 µL reaction volume (5 µL of sample).
    • Our 5,000 assay point kit allows you to run 5,000 wells in a 384-well format, using a 20 µL reaction volume (5 µL of sample).
    Features
    • No-wash steps, no separation steps
    • ELISA alternative technology
    • Sensitive detection
    • Small sample volume

    For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).

  • Assay Technology
    Alpha
    Automation Compatible
    Yes
    Brand
    AlphaLISA
    Detection Method
    Alpha
    Experimental Type
    In vitro
    Target Species
    Human
    Therapeutic Area
    Oncology